06/04/2021

Qualification of a method for the measurement of a potentially therapeutic protein

A recent project completed by Anapharm involved qualifying an analytical method for the measurement of a therapeutic protein in human skin tissue. The protein of interest is one that is expressed ubiquitously in a number of tissues and cell types.

While there are commercially available immunoassay kits to detect and measure this particular protein, the aim here was to develop a fit-for-purpose method, which produced reproducible results within a challenging matrix.

There were a number of factors that had a direct impact on the reproducibility of this assay and were addressed in the following ways:
• With limitations on the availability of the skin sample matrix and the presence of endogenous protein, a surrogate matrix of RIPA buffer was used.
• To maintain sample stability, samples were sliced on dry ice and removed only briefly for weighing.
• Cut samples were homogenised using the Precylls Evolution Homogeniser®, which allowed for the creation of repeatable programs at sub-zero temperatures.
• Additionally, during homogenisation, RIPA buffer, spiked with a protease inhibitor was added to prevent any enzyme degradation.
• To ensure that a similar amount of drug per mg of total protein was generated regardless of the size of sample section taken, a fixed ratio of RIPA buffer was added per mg of skin tissue.

In addition to method parameters normally assessed for a PK assay, such as precision and accuracy, selectivity, parallelism and stability, the qualification of this method also involved the evaluation and optimisation of the homogenization procedure. The use of an automated tissue homogeniser also helped in the generation of a highly reproducible homogenisation process, which then facilitated the completion of the qualification of a fit-for-purpose method.

Please find below the poster for your ready reference:

MORE NEWS

30/10/2020 12:49

Successful WHO Inspection

Anapharm Bioanalytics is proud to announce that it has successfully undergone World Health Organization GCP/GLP compliance inspection at its Barcelona based bioanalytical lab

READ MORE
08/05/2020 14:29

Cell Lab | Anapharm Bioanalytics expands its laboratory capabilities

We are glad to inform you that a cell lab has recently been built at our facilities in Barcelona. Our brand new cell lab capabilities will enable the development and validation of a variety of assays such as Cell Proliferation, Ligand Stimulated Cell Signalling, Protein Secretion, Reporter Gene, NAbs, etc.

READ MORE
31/03/2020 10:03

Anapharm Bioanalytics Brazilian ANVISA Certificate Renewal

Anapharm Bioanalytics is proud to announce that it has recently (February 20th, 2020) renewed its ANVISA (Brazil) certificate. The renewed certification is valid until February 20th, 2022.

READ MORE